Glassman Wealth Services grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 33.2% during the first quarter, HoldingsChannel.com reports. The firm owned 1,031 shares of the biopharmaceutical company’s stock after acquiring an additional 257 shares during the period. Glassman Wealth Services’ holdings in Gilead Sciences were worth $67,000 as of its most recent filing with the SEC.
Several other hedge funds have also recently made changes to their positions in GILD. Athena Capital Advisors LLC acquired a new position in shares of Gilead Sciences in the fourth quarter valued at about $27,000. Capital Financial Planning LLC acquired a new stake in Gilead Sciences during the fourth quarter worth about $27,000. Creative Financial Designs Inc. ADV grew its holdings in Gilead Sciences by 55.9% during the first quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 165 shares during the period. Claybrook Capital LLC acquired a new stake in Gilead Sciences during the fourth quarter worth about $32,000. Finally, Trustcore Financial Services LLC acquired a new stake in Gilead Sciences during the first quarter worth about $34,000. 78.78% of the stock is currently owned by institutional investors and hedge funds.
GILD has been the topic of several analyst reports. Maxim Group reaffirmed a “buy” rating and set a $84.00 target price on shares of Gilead Sciences in a report on Friday, March 29th. Mizuho set a $88.00 target price on Gilead Sciences and gave the stock a “buy” rating in a report on Friday, March 22nd. Oppenheimer set a $85.00 target price on Gilead Sciences and gave the stock a “buy” rating in a report on Tuesday, March 19th. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $69.00 target price on the stock in a report on Tuesday, April 23rd. Finally, UBS Group raised Gilead Sciences from a “neutral” rating to a “buy” rating and raised their target price for the stock from $75.00 to $77.00 in a report on Wednesday, April 10th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fifteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $79.54.
In other Gilead Sciences news, Director John Francis Cogan sold 2,700 shares of the firm’s stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $64.14, for a total value of $173,178.00. Following the sale, the director now directly owns 57,560 shares of the company’s stock, valued at $3,691,898.40. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Richard James Whitley sold 9,534 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $65.48, for a total value of $624,286.32. Following the completion of the sale, the director now directly owns 34,669 shares in the company, valued at $2,270,126.12. The disclosure for this sale can be found here. Over the last three months, insiders sold 28,602 shares of company stock worth $1,863,445. 0.20% of the stock is owned by corporate insiders.
Shares of GILD opened at $66.99 on Friday. The company has a current ratio of 3.62, a quick ratio of 3.53 and a debt-to-equity ratio of 1.09. Gilead Sciences, Inc. has a 12 month low of $60.32 and a 12 month high of $79.61. The company has a market capitalization of $85.14 billion, a price-to-earnings ratio of 10.34, a price-to-earnings-growth ratio of 0.64 and a beta of 1.10.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.53 by $0.23. Gilead Sciences had a return on equity of 37.98% and a net margin of 26.40%. The company had revenue of $5.28 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same period last year, the company earned $1.48 earnings per share. Gilead Sciences’s quarterly revenue was up 3.8% compared to the same quarter last year. Research analysts anticipate that Gilead Sciences, Inc. will post 6.6 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 3.76%. The ex-dividend date is Thursday, June 13th. Gilead Sciences’s payout ratio is currently 40.98%.
WARNING: “Glassman Wealth Services Increases Stake in Gilead Sciences, Inc. (NASDAQ:GILD)” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.dispatchtribunal.com/2019/06/14/glassman-wealth-services-increases-stake-in-gilead-sciences-inc-nasdaqgild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Featured Story: Market Capitalization in the Stock Market
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.